Low-density lipoprotein cholesterol response to statins according to comorbidities and co-medications: A...

Area of Science:

• Cardiovascular Medicine
• Pharmacology
• Clinical Pharmacy

Background:

• Statin therapy effectiveness in lowering low-density lipoprotein cholesterol (LDL-C) shows significant individual variability.
• This variability may be influenced by co-morbidities and co-medications, impacting treatment strategies.
• Investigating these factors is crucial for optimizing statin therapy in diverse patient populations.

Purpose of the Study:

• To determine if common co-morbidities and co-medications significantly impact individual patient responses to statin therapy.
• To identify specific patient subgroups that may benefit from adjusted statin regimens based on their health status and concomitant drug use.

Main Methods:

• A Danish register-based cohort study of 89,006 patients initiating simvastatin or atorvastatin between 2008-2018.
• LDL-C reduction was calculated as percentage reduction difference (PRD) from pre-statin to on-statin levels.
• Linear regression analyzed PRD across 175 comorbidities and 99 co-medications, assessing statistical and clinical significance (PRD ≥ 5%).

Main Results:

• Concomitant use of oral blood-glucose lowering drugs, primarily metformin, was linked to a clinically significant and statistically important enhanced statin response (PRD 5.18%).
• No other comorbidity or co-medication met the criteria for a clinically important effect on statin response.
• Collectively, comorbidities and co-medications explained only 1.7% of the total population variance in statin response.

Conclusions:

• Most studied comorbidities and co-medications do not clinically impact statin response, suggesting general treatment regimens are appropriate.
• Metformin use is associated with significantly improved LDL-C response to statins.
• This finding suggests potential for using lower statin doses in patients concurrently treated with metformin.